CYTOKINETICS INC

Listed Company

CYTKCIK 0001061983NasdaqLarge AcceleratedPharmaceutical PreparationsFY ends Dec 31

Period

FY 2025

Revenue

$88.04M

Net Income

$-785.00M

Total Assets

$1.42B

Equity

$-659.63M

Shares Out

124.43M

Op. Cash Flow

$-510.00M

CYTK$80.60+107.30% · past yearDBEQ Basic

Daily closing prices

Business

Cytokinetics is a biopharmaceutical company discovering and developing small-molecule muscle activators and inhibitors for cardiovascular and neuromuscular diseases. Its first approved product, MYQORZO (aficamten), a cardiac myosin inhibitor, treats symptomatic obstructive hypertrophic cardiomyopathy. The company is advancing omecamtiv mecarbil for heart failure with reduced ejection fraction, ulacamten for heart failure with preserved ejection fraction, and CK-089 for muscular dystrophy. Commercial distribution occurs through specialty sales forces; international expansion is supported by licensing partnerships with Sanofi and Bayer.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	88	18	8	95	70
Research and development	416	339	330	241	160
General and administrative	284	215	174	178	97
Total operating expenses	700	555	504	419	257
Operating loss	−612	−536	−496	−324	−186
Interest expense	−46	−38	−28	−19	−16
Non-cash interest expense on liabilities related to revenue participation right purchase agreements	−58	−49	−29	−32	−13
Interest and other income, net	48	52	28	11	331,000
Change in fair value of derivative liabilities	4	1	0	0	—
Change in fair value of liabilities related to RPI Transactions	−200,000	−20	0	0	—
Debt conversion expense	−121	0	0	—	—
Net loss	−785	−590	−526	−389	−215
Net loss per share - basic	−6.54	−5.26	−5.45	−4.33	−2.8
Net loss per share - diluted	−6.54	−5.26	−5.45	−4.33	−2.8
Weighted-average number of shares used in computing net loss per share - basic	120,103	111,979	96,524	89,825	76,886
Weighted-average number of shares used in computing net loss per share - diluted	120,103	111,979	96,524	89,825	76,886
Unrealized (loss) gain on available-for-sale securities, net	−990,000	2	4	−3	−1
Foreign currency translation adjustments	−778,000	255,000	−20,000	0	0
Comprehensive loss	−787	−587	−523	−392	−216

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	123	95	113	66	113
Short-term investments	760	981	502	717	359
Accounts receivable	18	17	1	147,000	52
Prepaid expenses and other current assets	17	15	12	12	12
Total current assets	917	1,108	628	795	536
Long-term investments	335	145	41	47	152
Property and equipment, net	79	66	69	80	73
Operating lease right-of-use assets	76	75	79	83	73
Other assets	17	8	8	10	7
Total assets	1,425	1,402	824	1,015	841
Accounts payable	22	20	22	26	21
Accrued liabilities	83	55	43	44	34
Short-term operating lease liabilities	19	19	18	13	15
Current portion of convertible and long-term debt	41	12	10	958,000	—
Derivative liabilities measured at fair value	31	11	0	—	—
Deferred revenue	2	52	0	—	—
Other current liabilities	4	10	11	1	2
Total current liabilities	202	180	103	85	72
Term loans, net	246	93	58	64	47
Convertible notes, net	870	552	—	—	—
Liabilities related to revenue participation right purchase agreements, net	521	462	380	301	179
Long-term operating lease liabilities	108	113	120	127	112
Liabilities related to RPI Transactions measured at fair value	137	137	0	—	—
Total liabilities	2,084	1,537	1,211	1,123	597
Commitments and contingencies	—	—	—	—	—
Preferred stock, $0.001 par value: Authorized: 10,000,000 shares; Issued and outstanding: none	0	0	0	0	0
Common stock, $0.001 par value: Authorized: 163,000,000 shares Issued and outstanding: 122,943,172 shares at December 31, 2025 and 118,209,139 shares at December 31, 2024	123,000	118,000	102,000	94,000	84,000
Additional paid-in capital	2,826	2,564	1,726	1,482	1,452
Accumulated other comprehensive income	630,000	2	−10,000	−4	−869,000
Accumulated deficit	−3,500	−2,702	−2,112	−1,586	−1,197
Total stockholders' deficit	−660	−135	−386	−108	244
Total liabilities and stockholders' deficit	1,425	1,402	824	1,015	841

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−785	−590	−526	−389	−215
Non-cash interest expense on liabilities related to revenue participation right purchase agreement	58	49	29	32	13
Stock-based compensation expense	112	98	72	48	27
Non-cash lease expense	6	4	4	3	7
Loss on disposition of property and equipment	0	45,000	0	0	—
Depreciation of property and equipment	10	10	12	6	2
Realized (loss) gain on investment, net	−25,000	−19,000	35,000	107,000	—
Interest receivable and amortization on investments	−16	−33	−16	−5	5
Non-cash interest expense related to debt	23	12	7	6	7
Accounts receivable	−1	−15	−1	57	−47
Prepaid and other assets	−3	−2	2	−7	−7
Accounts payable	3	−4	−3	5	1
Deferred revenue	−51	52	0	−87	0
Accrued and other liabilities	34	14	17	11	15
Operating lease liabilities	−11	−7	−1	2	43
Other non-current liabilities	−6	−1	−10	−4	4
Net cash used in operating activities	−510	−396	−414	−300	−143
Purchases of investments	−1,063	−1,293	−635	−855	−525
Investment in non-marketable equity security	−5	0	0	—	—
Maturities of investments	1,104	744	871	605	423
Sales of investments	6	0	5	0	3
Purchases of property and equipment	−25	−4	−1	−11	−49
Net cash (used in) provided by investing activities	17	−553	239	−262	−148
Repayment of finance lease liabilities	−204,000	−939,000	−858,000	−944,000	0
Repayment of term loan	−11	−9	0	−48	0
Repayment of convertible debt	−403	0	0	−140	0
Proceeds from issuance of convertible debt, net	729	0	0	524	0
Proceeds from draw on RPI Multi Tranche Loan	175	200	50	—	—
Proceeds from issuance of common stock related to private placement, net of issuance costs	0	50	0	0	15
Proceeds from issuance of common stock under equity incentive and stock purchase plans	36	53	18	18	12
Taxes paid related to net share settlement of equity awards	−2	−20	−11	−10	−4
Net cash provided by financing activities	524	931	221	516	320
Effect of exchange rate changes	−715,000	209,000	−20,000	—	—
Net (decrease) increase in cash, cash equivalents, and restricted cash	30	−18	46	−45	30
Cash paid for interest	23	26	10	15	9
Right-of-use assets recognized in exchange for operating lease obligations	6	481,000	0	11	80
Amounts unpaid for purchases of property and equipment	3	3	0	621,000	12
Issuance of common stock in connection with repurchase of convertible note	108	0	0	317	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is CYTOKINETICS INC's CIK number?

CYTOKINETICS INC's SEC CIK number is 0001061983 (1061983). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find CYTOKINETICS INC's SEC filings?

All of CYTOKINETICS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did CYTOKINETICS INC last report earnings?

CYTOKINETICS INC (CYTK) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-206360). This is CYTOKINETICS INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is CYTOKINETICS INC's most recent earnings 8-K?

CYTOKINETICS INC's latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0001193125-26-206360. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View CYTOKINETICS INC's latest earnings 8-K →
Look up any company's CIK number →